Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Variant||FGFR2 - DDX21|
|Gene Variant Descriptions||FGFR2-DDX21 results from the fusion of FGFR2 and DDX21 (PMID: 30745300). FGFR2-DDX21 has been identified in cholangiocarcinoma (PMID: 30745300, PMID: 28642281), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Apr 2022).|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - DDX21||cholangiocarcinoma||sensitive||Debio 1347||Case Reports/Case Series||Actionable||In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with cholangiocarcinoma harboring FGFR2-DDX21 (PMID: 30745300; NCT01948297).||30745300|
|FGFR2 - DDX21||cholangiocarcinoma||sensitive||Debio 1347||Case Reports/Case Series||Actionable||In a clinical case study, treatment with Debio 1347 resulted in stable disease for 5.5 months in a patient with cholangiocarcinoma harboring an FGFR2-DDX21 fusion (PMID: 34250419).||34250419|
|FGFR2 - DDX21 FGFR2 K659M FGFR2 Y779C||cholangiocarcinoma||predicted - resistant||Debio 1347||Case Reports/Case Series||Actionable||In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-DDX21 fusion experienced disease progression after 5.5 months of treatment with Debio 1347 and was found to have acquired additional FGFR2 mutations, K659M and Y779C (PMID: 34250419).||34250419|